Recent News

• 02.02.2026 - vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
• 12.18.2025 - vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
• 11.06.2025 - vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.09.2025 - vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
• 09.15.2025 - vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
• 09.10.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference

Recent Filings

• 02.02.2026 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 12.09.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.24.2025 - EFFECT Notice of Effectiveness
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 10.03.2025 - S-3 Registration statement under Securities Act of 1933
• 09.25.2025 - 4 Statement of changes in beneficial ownership of securities